VP-VLY-686-3301 Vanda Pharmaceuticals, Inc.
Clinical Study Protocol 27 October 2022
1
CONFIDENTIALTRADIPITANT 
AMENDMENT NO. 6 TO PROTOCOL VP-VLY-686-3301
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND,
PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS 
THE EFFICACY OF TRADIPITANT IN RELIEVING
SYMPTOMS OF GASTROPARESIS 
Author: Jesse Carlin, Ph.D
Document Type: Clinical Study Protocol
Sponsor: Vanda Pharmaceuticals Inc.
2200 Pennsylvania Ave. NW
Suite 300E
Washington, DC 20037
USA
Study Product: tradipitant (VLY-686)
Protocol Number: VP-VLY-686-3301
Study Phase: III
IND Number: 131545
Date: 27 October 2022
Status: Final
Number of Pages: 76
VP-VLY-686-3301 Vanda Pharmaceuticals, Inc.
Clinical Study Protocol 27 October 2022
2
CONFIDENTIALSIGNATURE PAGE FOR VANDA PHARMACEUTICALS INC.
Amendment No. 6 to VP-VLY-686-3301
Approved by the following:
Program Lead :
Gunther Birznieks Date
Senior Vice President, Research & 
Development Committee
Medical Director:
Christos Polymeropoulos , M.D. Date
Medical Director
	

	
VP-VLY-686-3301 Vanda Pharmaceuticals, Inc.
Clinical Study Protocol 27 October 2022
3
CONFIDENTIALName of Sponsor/Company:
Vanda Pharmaceuticals Inc.
Name of Investigational Product:
Tradipitant (VLY-686)
Name of Active Ingredient:
{2-[1-(3,5-Bistrifluoromethylbenzyl)-5-pyridin-4- yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-
chlorophenyl)-methanone
Title of Study: A Multicenter, Randomized, Double-Blind, Placeb o-Controlled Phase III Study to Assess 
the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis
Study center(s): Approximately 50 centers in the United States
Indication: 
Diabetic & Idiopathic GastroparesisPhase of development: 
III
Number of subjects (planned): 
Up to 800 subjects will enroll in the study. 
Group 1: Approximately 200 gastroparesis subjects will be determined eligible to enter the Evaluation 
Phase and be randomized to one of 2 arms (100 per arm, 1:1 randomization scheme).
Group 2: Up to  600 gastroparesis subjects that are not eligible to be randomized will enter into the 12 
week Open Label Phase of the study.  
Inclusion Criteria:
1.Male and female subjects aged 18 â€“70 years (inclusive);
2.Diagnosed with gastroparesis:
a. Demonstrated delayed gastric emptying  of a solid meal via either scintigraphy, gastric 
breath test, or wireless motility capsu le within 10 years of screening . If solid meal is not 
tolerated, a liquid meal may be us ed instead to demonstrate delayed gastric emptying via 
scintigraphy
b. Presence of nausea symptom for at leas t 6 months prior to screening
3.Patient â€™s gastroparesis symptoms persist despite diet and/or life -style modifications;
4.Body Mass Index (BMI) of â‰¥18 and <4 0k g / m2(BMI = weight (kg)/ [height (m)]2);
5.Subjects must agree to the fo llowing study restrictions:  
a.Males of procreative capacity (not surgically  sterile) will use an acceptable method of 
contraception from randomization through 1 mo nth following the last dose of study 
medication. Examples of acc eptable contraception for males include abstinence, use of 
a barrier method, or sterilized or post-menopausal partner; 
b. Females of child-bearing potential (not surgically sterile or post- menopausal, defined as 
12 months without menses) will use an acceptable method of contraception from 1 
month prior to randomization (or screening, if earlier) through 1 month following the 
last dose of study medication. Examples of acceptable methods of contraception for 
females include abstinence , double barrier method, IU D, hormonal contraception, or 
sterilized partner; 
VP-VLY-686-3301 Vanda Pharmaceuticals, Inc.
Clinical Study Protocol 27 October 2022
4
CONFIDENTIAL6.Ability and acceptance to provide written informed consent; 
7.Willing to participate in the ph armacogenomics sample collection;
8.Willing and able to comply with all study requ irements and restrictions, including but not limited 
to: 
a. Daily symptom diary completion,
a. Prohibited medications,
b. Strict control of blood glucose (T1DM and T2DM patients);
9.Willing to not participate in any oth er interventional trial for the duration of their participation.
NOTE: ADDITIONAL CRITERIA ARE CONFIDENTIAL AND SHOULD NOT BE 
SHARED WITH SUBJECTS, POTENTIAL SUBJECTS, OR ANYONE OUTSIDE OF 
THE IMMEDIATE STUDY TEAM.
Additional Inclusion Criteria for Group 1/Evaluation Phase:
10.Diagnosed with idiopathic or diabetic gastrop aresis with moderate to severe nausea: 
a. At least 24 screening diary entries, 
b. PAGI-SYM individual nausea score â‰¥ 2 at Visit 1, and
c. Average daily diary nausea severity â‰¥ 2.5 during the screening period ,
d. At least one episode of vomiting during the screening period.
Additional Inclusion Criteria for Group 2/Open Label Phase:
11.Diagnosed with diabetic, idiopathic, post-surgical or viral gastroparesis,
a. Presence of nausea (PAGI-SYM individual nausea score â‰¥ 1 at Visit 1) ,
b. At least 24 screening diary entries,
c. Patients who do not qualify for Group 1/Evaluation Phase.
Exclusion Criteria:
1.Another active disorder or treatment which could explain or contribute to symptoms in the 
opinion of the Investigator (including but not limited to gastric malignancy, neurological 
disorder, or heavy doses of strong anticholinergics); 
2.Gastric or parenteral feeding within 4 weeks of screening for Group 1;
3.Pregnancy or nursing; 
4.History of intolerance and/or hypersensitivity  to medications similar to tradipitant and its 
accompanying excipients;
5.History (including family history) or current evidence of congenital long QT syndrome or 
known acquired QT interval prolongation ( including QTcF > 450 in males or > 470 in females
at screening);
VP-VLY-686-3301 Vanda Pharmaceuticals, Inc.
Clinical Study Protocol 27 October 2022
5
CONFIDENTIAL6.History of suicide attempt and/or suicidal ideatio n (of type 4 or 5 on the Columbia Suicide 
Severity Rating Scale (C-SSRS)) within 2 years of screening or subject is at risk of suicide at 
Screening or Baseline visits, in the opinion of the investigator; 
7.History of an eating disorder within 2 years of screening for Group 1 only and within 3 months 
of screening for Group 2;
8.Recent history (within six months of screenin g) of Alcohol Use Disorder or Substance Use 
Disorder as defined in DSM- 5 or evidence of such abuse wh ich may include a positive drug 
screen at the Screening visit and does not include medical marijuana for Group 2 subjects only 
9.Uncontrolled thyroid disease;
10.Unstable cardiac, respiratory, hepatic or renal disease;
11.Indication of impaired liver function (inclu ding values for AST, ALT, or bilirubin > 2 times the 
Upper Limit of Normal, unless isolated bilirubin > 2 x ULN due solely to Gilbertâ€™s syndrome) at
screening;
12.Has a creatinine level > 2x ULN at screening;
13.Anyone affiliated with the site or sponsor an d/or anyone who may consent under duress; 
14.Any other reason as determined by the Inves tigator which may lead to an unfavorable risk-
benefit of study participation, may interfere with study compliance, or may confound study 
results;
15.Evidence of uncontrolled blood glucose (in cluding HbA1C >9 for Group 1 or HbA1C > 11 for
Group 2 at screening or metabolic crisis in past 60 days);
16.Surgeries to the stomach including gast rectomy, fundoplication, vagotomy, pyloroplasty, 
bariatric surgery excluded in Group 1 and ex cluded in Group 2 if performed <  2 months from 
screening . Additionally, gastric stimulation device surgically implanted  within the last year or if 
implanted more than a year ago for  Group 1 subjects or withing the last 2 months for Group 2
subjects, or have changed stimulation settings within the last 3 months (i e gastric stimulation 
device must have a stable setting for at least 3 months) for Group 1 and withing the last 1 month 
for Group 2 subjects
17.Use of prohibited medication or medicatio n with anti-nausea, antiemetic, neuro modulating, or 
prokinetic effect within 2 weeks of the screening visit EXCEPT when administered on a stable 
daily dosing schedule (stable for at least 3 months pr ior to the screening visit) or administered 
under protocol-specified re scue medication guidelines; 
18.Use of the following within 2 weeks of screening: another NK- 1 antagonist or a second generation 
5-HT3 antagonist for Group 1 and Group 2,  phenergan more than 2 times per day for Group 1 
only, or opioids more than 2 times per week for Group 1 only;
19.Pyloric injection of neur otoxins (e.g. botulinum type A or B) within 3 months of the Screening 
Visit for Group 1 or  within 1 month of Screening for Group 2;
20.Exposure to any investigatio nal medication, including placebo , within 60 days of the Baseline 
Visit;
VP-VLY-686-3301 Vanda Pharmaceuticals, Inc.
Clinical Study Protocol 27 October 2022
6
CONFIDENTIAL21.Patients who previously participated in stud y VP-VLY-686-2301 or any other clinical study of 
tradipitant in the past. 
Investigational product, dosage and mode of administration: 
Group 1: Oral 85 mg tradipitant and matching placebo capsules will be administered. Subjects will be 
randomized to one of t wo treatment arms to receive 85 mg tradipitant BID or placebo.  
Group 2: Open label Oral 85 mg tradipitant capsules will be  administered to all group 2 patients. 
All subjects will be instructed to take 1 capsule in the morning and another approximatel y 12 hours later 
in the evening.
Duration of treatment: Up to 12 weeks
Objectives: 
Primary:
xTo evaluate the efficacy of trad ipitant relative to placebo in change from baseline to 
Week 12 in the daily nausea severity scores.
Secondary:
xTo evaluate the efficacy of tradipitant r elative to placebo in change from baseline in number 
of days at â€œ0â€ nausea .
xTo evaluate the efficacy of tradipitant relativ e to placebo in change from baseline of other 
individual symptoms associated with gastroparesis.
xTo evaluate the efficacy of tradipitant relative to placebo in change from baseline of the 
overall symptom burden associated with gastroparesis.
xTo evaluate the efficacy of tradipitant relative to placebo in change from baseline of global 
improvement and quality of life measures.
xTo explore the safety and tolerability of multiple oral doses of tradipitant. 
Overall Design:
This is a multi center, randomized, double-blind, placebo- controlled study to be conducted in the United 
States. Up to eight hundred (800 ) subjects diagnosed with gastroparesis, who satisfy the selection criteria 
for the study, will be eligible for one of two groups. Group 1 will ente r the Evaluation Ph ase of the study 
and Group 2 will enter the Open Label phase of the study.  Patients eligib le for Group 1 will be randomized 
to one of t wotreatment groups. Randomization will be str atified by disease etiology (idiopathic or 
diabetic), a nd enrollment for either of the etiologies will be capped at 60% of the total sample size. Patients 
eligible for Group 2 will enter the Open Label Phase of the study.
The study includes two phases: the screening phase and  the evaluation phase. The screening phase 
includes a screening visit to evaluate subjectsâ€™ prelimin ary eligibility for the study. During the screening 
phase, subjects will collect diary data for at least 4 weeks. The data collected during the screening phase 
must be reviewed in order to determine eligibility for enrollment into the evaluation phase. Data review 
will be performed prior or at Visit 2. Patients who to  meet all Group 1 eligibility criteria will 
randomized onto double blind treatment in the evaluation phase . Patients who meet Group 2 criteria or 
do not meet symptom criteria for ra ndomization but still meet all other eligibility criteria, will be offered
open label treatment in the open label arm of the e valuation phase. When enrollment goal is reached for 
VP-VLY-686-3301 Vanda Pharmaceuticals, Inc.
Clinical Study Protocol 27 October 2022
7
CONFIDENTIALgroup 1, group 1 enrollment will be closed and all subseq uent  patients in screening will be evaluated for 
group 2 eligibility only. 
The Evaluation Phase includes 12 weeks of double blind randomized treatment of placebo or tradipitant 
(85mg bid, approximately 12 hours apart )f o r  G r o u p  1  or open label tradipitant (85mg bid, approximately 
12 hours apart)  for Group 2. Daily diaries will be co mpleted during all phases. Clinical evaluations and
safety assessments will occur at Screening, Baseline, Week 2, Week 4, Week 6, Week 8, Week 10, and 
Week 12 .
Following the End of Study Vi sit (Visit 8) patients can opt -in to a one- day optional pharmacokinetic (PK) 
study where one additional do se of tradipitant will be taken and blood will be drawn pre-dose and, 1, 2, 
4, 6, 8 -hour post dose to assess drug lev els. This optional PK Visit can occur 1- 14 days after Visit 8.  
Primary Endpoint: 
Change from baseline to Week 12 in daily individual nausea severity scores (0=no ne, 1=very mild, 2= 
mild, 3=moderate, 4=severe, 5=very severe)
Criteria for evaluation:
Efficacy :
Efficacy assessments will include: 
xGastroparesis Core Symp tom Daily Diary (GCSDD)
xPatient Assessment of GI Disorders â€“Symptoms Severity Index (PAGI-SYM)
xGlobal Assessment of Gastroparesis
xPatient Rated Change in Gastroparesis Symptoms
xPatient Global Impression â€“Change (PGI-C)
xPatient Assessment of Gastrointestinal Disorders â€“Quality of Life (PAGI-QOL)
xGastroparesis Treatment Benefit Survey (GTBS)
xClinician Global Impression â€“Severity (CGI-S)
Safety: 
xSafety and tolerability assessments will inclu de the recording of adverse events (AEs), 
physical examinations, clinical laboratory evaluati ons, vital signs, and electrocardiograms.
xThe Columbia-Suicide Severity Scale (C- SSRS) will be used to assess suicidal behavior and 
ideation.
Sample Size Discussion: 
Based on a two -sided t-test with the 5% significance level, the planned sample size of 100 subjects per 
arm provides 95% power to detect a mean difference of 0.65 point in the average of daily nausea severity 
assuming the standard deviation of 1.25 in each treatment group. 